Inhibition of human immunodeficiency virus type 1 Tat activity by coexpression of heterologous trans activators

We examined the mechanism of Tat-mediated trans activation through competition experiments employing Tat proteins of human immunodeficiency virus type 1 (HIV-1) and equine infectious anemia virus (EIAV). EIAV Tat, as well as chimeric EIAV/HIV-1 Tat proteins, inhibited HIV-1 Tat-mediated trans activation in a cell-type-dependent fashion. Furthermore, these proteins inhibited trans activation by Tat-bacteriophage R17 coat protein chimeras. Inhibition resulted from competition between activation domains of effectors and competitors for a limiting cellular cofactor. The context in which competitor activation domains were expressed contributed to the extent of inhibition. In transfected cells, EIAV Tat and all chimeric competitors were located primarily in the cytoplasm, whereas HIV-1 Tat was primarily located in the nucleus. These data are consistent with a model for trans activation in which the activation domain of Tat associates with and conveys a cellular factor to the transcription complex via the trans-acting-responsive element (TAR).

[1]  D. Capon,et al.  Regulation of mRNA accumulation by a human immunodeficiency virus trans-activator protein , 1987, Cell.

[2]  F. Carlotti,et al.  Structural analysis of wild-type and mutant human immunodeficiency virus type 1 Tat proteins , 1990, Journal of virology.

[3]  P. Luciw,et al.  Anti-termination of transcription within the long terminal repeat of HIV-1 by tat gene product , 1987, Nature.

[4]  B. Cullen,et al.  Mutational analysis of the trans-activation-responsive region of the human immunodeficiency virus type I long terminal repeat , 1988, Journal of virology.

[5]  T. Kunkel.  Rapid and efficient site-specific mutagenesis without phenotypic selection. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[6]  C. Rosen,et al.  A cDNA for a protein that interacts with the human immunodeficiency virus Tat transactivator. , 1990, Science.

[7]  P. Luciw,et al.  Cellular factors regulate transactivation of human immunodeficiency virus type 1 , 1991, Journal of virology.

[8]  M. Ptashne.  How eukaryotic transcriptional activators work , 1988, Nature.

[9]  A. Srinivasan,et al.  Functional substitution of the basic domain of the HIV-1 trans-activator, Tat, with the basic domain of the functionally heterologous Rev. , 1990, Virology.

[10]  P. Sharp,et al.  HIV TAR: An RNA enhancer? , 1989, Cell.

[11]  C. Debouck,et al.  Trans-dominant Tat mutants with alterations in the basic domain inhibit HIV-1 gene expression. , 1991, The New biologist.

[12]  P. Luciw,et al.  Structure, sequence, and position of the stem-loop in tar determine transcriptional elongation by tat through the HIV-1 long terminal repeat. , 1989, Genes & development.

[13]  B. Berkhout,et al.  Down modulation of HIV-1 gene expression using a procaryotic RNA-binding protein. , 1990, Nucleic acids research.

[14]  S. Arya,et al.  Trans-activator gene of human T-lymphotropic virus type III (HTLV-III). , 1985, Science.

[15]  D. Derse,et al.  Mutational analysis of the equine infectious anemia virus Tat-responsive element , 1991, Journal of virology.

[16]  M. Malim,et al.  Mutational analysis of the conserved basic domain of human immunodeficiency virus tat protein , 1989, Journal of virology.

[17]  G. Stormo,et al.  RNA binding site of R17 coat protein. , 1987, Biochemistry.

[18]  B. Peterlin,et al.  A minimal lentivirus Tat , 1991, Journal of virology.

[19]  J. Hess,et al.  Nucleotide sequence and transcriptional activity of the caprine arthritis-encephalitis virus long terminal repeat , 1986, Journal of virology.

[20]  B. Cullen.  The HIV-1 Tat protein: An RNA sequence-specific processivity factor? , 1990, Cell.

[21]  C. Morency,et al.  A novel rapid assay for chloramphenicol acetyltransferase gene expression , 1987 .

[22]  J. Sodroski,et al.  Location of the trans-activating region on the genome of human T-cell lymphotropic virus type III. , 1985, Science.

[23]  N. Sonenberg,et al.  A bulge structure in HIV-1 TAR RNA is required for Tat binding and Tat-mediated trans-activation. , 1990, Disease markers.

[24]  D M Crothers,et al.  Fragments of the HIV-1 Tat protein specifically bind TAR RNA. , 1990, Science.

[25]  J. Karn,et al.  Human immunodeficiency virus 1 tat protein binds trans-activation-responsive region (TAR) RNA in vitro. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[26]  J. Maio,et al.  RNA transcripts of the human immunodeficiency virus transactivation response element can inhibit action of the viral transactivator. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[27]  S. Ruben,et al.  Structural and functional characterization of human immunodeficiency virus tat protein , 1989, Journal of virology.

[28]  M. Ishino,et al.  Mutational analysis of HIV-1 Tat minimal domain peptides: Identification of trans-dominant mutants that suppress HIV-LTR-driven gene expression , 1989, Cell.

[29]  P. Dorn,et al.  Equine infectious anemia virus tat: insights into the structure, function, and evolution of lentivirus trans-activator proteins , 1990, Journal of virology.

[30]  R. Gaynor,et al.  A transdominant tat mutant that inhibits tat-induced gene expression from the human immunodeficiency virus long terminal repeat. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[31]  B. Peterlin,et al.  Trans-activation by HIV-1 Tat via a heterologous RNA binding protein , 1990, Cell.

[32]  J. Lisziewicz,et al.  Tat-regulated production of multimerized TAR RNA inhibits HIV-1 gene expression. , 1991, The New biologist.

[33]  Michael R. Green,et al.  Activation of transcription by HIV-1 Tat protein tethered to nascent RNA through another protein , 1990, Nature.

[34]  D. Derse,et al.  Identification of lentivirus tat functional domains through generation of equine infectious anemia virus/human immunodeficiency virus type 1 tat gene chimeras , 1991, Journal of virology.

[35]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[36]  T. Nguyen,et al.  Sequence-specific interaction of Tat protein and Tat peptides with the transactivation-responsive sequence element of human immunodeficiency virus type 1 in vitro. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[37]  A. van der Eb,et al.  A new technique for the assay of infectivity of human adenovirus 5 DNA. , 1973, Virology.

[38]  M. Mathews,et al.  HIV-1 Tat protein increases transcriptional initiation and stabilizes elongation , 1989, Cell.

[39]  L. Sherman,et al.  Identification of sequences encoding the equine infectious anemia virus tat gene. , 1990, Virology.

[40]  J. Sodroski,et al.  The location of cis-acting regulatory sequences in the human T cell lymphotropic virus type III (HTLV-III/LAV) long terminal repeat , 1985, Cell.

[41]  K. Jones,et al.  In vitro formation of short RNA polymerase II transcripts that terminate within the HIV-1 and HIV-2 promoter-proximal downstream regions. , 1989, Genes & development.